Dechra Pharmaceuticals PLC Pre Annual General Meeting Statement (1377U)
October 20 2017 - 2:00AM
UK Regulatory
TIDMDPH
RNS Number : 1377U
Dechra Pharmaceuticals PLC
20 October 2017
Friday, 20 October 2017
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Pre Annual General Meeting Statement
The Board of Dechra issues the following trading update prior to
the Annual General Meeting (AGM) which will take place at 1.00pm
today, Friday 20 October 2017, at The Mere Hotel, Chester Road,
Knutsford, Cheshire WA16 6LJ.
The Company is pleased to report that performance in the first
quarter of our financial year was in line with management
expectations, with continued growth across all of its markets.
No other new trading updates are to be made at the AGM
today.
Dechra will announce its interim results for the six month
period to 31 December 2017 on 26 February 2018.
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0)
1606 814 730
Richard Cotton, Chief Financial Office: +44 (0)
Officer 1606 814 730
e-mail: corporate.enquiries@dechra.com Office: +44 (0)
1606 814 730
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0)
e-mail: fiona@tooleystreet.com 7785 703 523
Office: +44 (0)
121 309 0099
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and relates products business. Our expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements.
The forward-looking statements reflect the knowledge and
information available to the Company during the preparation and up
to the publication of this document. By their very nature, these
statements depend upon circumstances and relate to events that may
occur in the future thereby involve a degree of uncertainty.
Therefore, nothing in this document should be construed as a profit
forecast by the Company.
Market Abuse Regulation (MAR)
The information contained within this announcement may
constitute inside information stipulated under the Market Abuse
Regulation (EU) No. 596/2014. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMOKCDDFBDDFKD
(END) Dow Jones Newswires
October 20, 2017 02:00 ET (06:00 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024